文献速递皮肤肿瘤

基于代谢评分的皮肤鳞状细胞癌预测肿瘤特征及对二氢乳清酸脱氢酶抑制剂治疗的反应

Metabolism-based scoring of cutaneous squamous cell carcinoma to predict tumour features and responses to treatment with dihydroorotate dehydrogenase inhibitors.
PubMed 文献 · Br J Dermatol · 2025-01-01

研究对从光化性角化病到转移性cSCC的患者样本进行蛋白质组和生物能量学分析,识别出低、中、高代谢评分三个亚组。在患者来源肿瘤细胞和异种移植模型中,肿瘤对来氟米特(DHODH抑制剂)的敏感性与代谢评分呈负相关,与DHODH蛋白表达水平呈正相关;DHODH过表达可使不敏感组变为敏感。

要点

  • cSCC存在低、中、高代谢评分三个亚组,跨越所有癌变阶段。
  • 肿瘤对来氟米特敏感性随代谢评分升高而降低,随DHODH表达升高而增强。
  • DHODH是低代谢评分cSCC亚组的潜在治疗靶点。

核心结论

  • 代谢评分可用于筛选对DHODH抑制剂来氟米特敏感的cSCC亚组,低代谢评分者更可能获益。

研究设计与样本

  • 对代表cSCC不同阶段(从光化性角化病到转移性cSCC)的患者样本进行蛋白质组和生物能量学分析。
  • 使用患者来源肿瘤细胞(PDC)和患者来源异种移植(PDX)模型,将肿瘤细胞和新鲜切除的患者肿瘤移植到免疫缺陷小鼠中。

主要发现

  • 在所有癌变阶段中识别出低、中、高代谢评分三个亚组。
  • 在PDC和PDX模型中,肿瘤对来氟米特的敏感性与代谢评分呈负相关,与DHODH蛋白表达水平呈正相关。
  • 在无反应组中过表达DHODH可使其对来氟米特敏感。

临床怎么用

  • 可考虑对cSCC进行代谢评分以识别可能对DHODH抑制剂来氟米特治疗反应更好的低代谢评分患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Alteration in metabolic activities is a critical step in cancer progression. Myriad metabolic-based therapy options are increasingly being proposed for human tumours. However, emerging evidence highlights interpatient metabolic heterogeneity and underscores the importance of metabolic phenotyping in cancer treatment. OBJECTIVES: To investigate metabolic heterogeneity in cutaneous squamous cell carcinoma (cSCC) and its impact on cSCC characteristics and treatment responses. METHODS: We applied combined proteomic and bioenergetic analyses to patient samples representing various stages of cSCC, ranging from precancerous actinic keratosis to metastatic cSCC. To investigate the functional impacts of the identified metabolic heterogeneities on tumour characteristics and treatment responses, we used patient-derived tumour cell (PDC) and patient-derived xenograft (PDX) models by transplanting tumour cells and freshly resected patient tumours into immunocompromised mice. RESULTS: Three subgroups with low, medium and high metabolic scores, respectively, were identified across all stages of carcinogenesis. Functional analyses indicated that, in both models (PDC and PDX), the sensitivities of tumours to leflunomide, an inhibitor of dihydroorotate dehydrogenase (DHODH), were inversely correlated with their metabolic scores and directly correlated with DHODH protein expression level. Moreover, DHODH overexpression in nonresponding groups rendered them sensitive to leflunomide. CONCLUSIONS: The findings demonstrate the relevance of metabolic profiling and scoring in the design of therapeutic approaches targeting the bioenergetic vulnerabilities of tumours and suggest DHODH as a promising therapeutic target in the low metabolic score subgroup of cSCC. Cutaneous squamous cell carcinoma (cSCC) is the second most common type of skin cancer. The number of cases is rising due to ageing populations and exposure to UV light. Most patients with cSCC have a good outcome. But, aggressive forms of cSCC can lead to poor outcomes and even death. We need new treatments and ways to find patients with cSCC who may respond well to specific therapy. Cancer cell metabolism is the way in which tumour cells generate energy. This plays a crucial role in how cancer cells behave and respond to treatment. In this study, we created a metabolic scoring system to classify cSCC tumours. We investigated how these scores relate to tumour characteristics and treatment responses. Using cSCC samples and comparing them to healthy skin, we found three cSCC subgroups. These subgroups had low, medium and high metabolic scores. cSCC tumours with low metabolic scores responded better to a drug called ‘leflunomide’. Leflunomide targets a key enzyme in metabolism called ‘dihydroorotate dehydrogenase’ (DHODH). cSCC tumours became sensitive to leflunomide when the levels of DHODH were higher. A metabolic scoring system could help personalize treatment for patients with cSCC. It may help find people who respond well to treatments targeting tumour metabolism. Treatments that target DHODH are promising in cSCC tumours with low metabolic scores.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Dousset L, Khalife F, Chalopin-Fillot D, et al. Metabolism-based scoring of cutaneous squamous cell carcinoma to predict tumour features and responses to treatment with dihydroorotate dehydrogenase inhibitors. Br J Dermatol. 2025. PMID: 40577595. doi:10.1093/bjd/ljaf253

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。